BMY ▼ -0.7% - Bristol-Myers Squibb Company
$BMY Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
23-OCT-2026 07:31 AM ET
Share this post
More filings for $BMY
BMY ▼ -0.6% - Bristol-Myers Squibb CompanyOct 23, 2026BMY ▲ +4.6% - Bristol-Myers Squibb CompanyOct 12, 2026BMY ▲ +4.6% - Bristol-Myers Squibb CompanyOct 12, 2026BMY ▲ +0.2% - Bristol-Myers Squibb CompanyOct 8, 2026BMY ▼ -2.1% - Bristol-Myers Squibb CompanySep 29, 2026BMY ▼ -2.1% - Bristol-Myers Squibb CompanySep 29, 2026
View full $BMY filing history →💬 Comments
Loading comments…
Leave a comment